{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:06:31Z","timestamp":1774404391456,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.cmi.2020.06.032","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T02:57:00Z","timestamp":1593745020000},"page":"1416.e5-1416.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Expression of CTX-M-15 limits the efficacy of ceftolozane\/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model"],"prefix":"10.1016","volume":"26","author":[{"given":"J.","family":"Canovas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Petitjean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Le Monnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Fantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.06.032_bib1","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.032_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-Day mortality for patients with Escherichia coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.06.032_bib4","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib5","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.032_bib7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.06.032_bib8","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1093\/jac\/dky283","article-title":"Activity of fosfomycin alone or combined with temocillin in\u00a0vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli","volume":"73","author":"Berleur","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.02018-15","article-title":"Cefotaxime and amoxicillin-clavulanate synergism against extended-spectrum-\u03b2-lactamase-producing Escherichia coli in a murine model of urinary tract infection","volume":"60","author":"Rossi","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib10","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/jac\/dkw066","article-title":"Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli","volume":"71","author":"Alexandre","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.06233-11","article-title":"Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum \u03b2-lactamase","volume":"56","author":"Lepeule","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01449-17","article-title":"Pharmacokinetics and tissue penetration of ceftolozane-tazobactam in diabetic patients with lower limb infections and healthy adult volunteers","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1471-2334-12-149","article-title":"Molecular epidemiology of extended-spectrum \u03b2-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15","volume":"12","author":"Park","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2020.06.032_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00160-19","article-title":"Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum \u03b2-lactamases from U.S. hospitals","volume":"63","author":"Castanheira","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dky453","article-title":"OXA-1 \u03b2-lactamase and non-susceptibility to penicillin\/\u03b2-lactamase inhibitor combinations among ESBL-producing Escherichia coli","volume":"74","author":"Livermore","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.06.032_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20303785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:18Z","timestamp":1761117918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20303785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1198743X20303785"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.06.032","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of CTX-M-15 limits the efficacy of ceftolozane\/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}